loading page

A self-assembled nanomedicine for glucose supply interruption-amplified low-temperature photothermal therapy and anti-prometastatic inflammatory processes of triple-negative breast cancer
  • +4
  • MingCheng Wang,
  • Huixi Yi,
  • Zhixiong Zhan,
  • Zitong Feng,
  • Gang-Gang Yang,
  • Yue Zheng,
  • Dong-Yang Zhang
MingCheng Wang
The Fifth Affiliated Hospital of Guangzhou Medical University
Author Profile
Huixi Yi
The Fifth Affiliated Hospital of Guangzhou Medical University
Author Profile
Zhixiong Zhan
The Fifth Affiliated Hospital of Guangzhou Medical University
Author Profile
Zitong Feng
The Fifth Affiliated Hospital of Guangzhou Medical University
Author Profile
Gang-Gang Yang
Anhui University School of Chemistry and Chemical Engineering
Author Profile
Yue Zheng
Sun Yat-Sen Memorial Hospital
Author Profile
Dong-Yang Zhang
The Fifth Affiliated Hospital of Guangzhou Medical University

Corresponding Author:zhangdy7@gzhmu.edu.cn

Author Profile

Abstract

The poor prognosis of triple-negative breast cancer (TNBC) resulting from its high metastasis, whereas inflammation accompanied by excessive reactive oxygen species (ROS) is prone to aggravate tumor metastasis. Although photothermal therapy (PTT) has extremely high therapeutic efficiency, the crafty tumor cells allow increase the expression of heat shock proteins to limit its effect, and PTT induced inflammation is also thought to be a potential trigger for tumor metastasis. Herein, myricetin, iron ions and polyvinylpyrrolidone were utilized to develop nanomedicines by self-assembly strategy for the treatment of metastatic TNBC. The nanomedicines with marvellous water solubility and dispersion can inhibit glucose transporter 1 and interfer with mitochondrial function to block the energy supply of tumor cells, achieving starvation therapy on TNBC cells. Nanomedicines with excellent photothermal conversion properties allow down-regulate the expression of HSPs to enhance the effect of PTT. Interestingly, the broad spectrum of ROS scavenging ability of nanomedicines successfully attenuat PTT induced inflammation as well as regulate metastasis-related proteins through glycometabolism inhibition to reduce tumor cell metastasis. Moreover, the nanomedicines have negligible side effects and good clinical application prospect, which provides a valuable paradigm for the treatment of metastatic TNBC through glycometabolism interference, anti-inflammation, starvation and photothermal synergistic therapy.
03 Apr 2024Submitted to Aggregate
07 Apr 2024Submission Checks Completed
07 Apr 2024Assigned to Editor
08 Apr 2024Reviewer(s) Assigned
10 Apr 2024Review(s) Completed, Editorial Evaluation Pending
03 Jun 2024Reviewer(s) Assigned
06 Jun 2024Review(s) Completed, Editorial Evaluation Pending
08 Jun 2024Editorial Decision: Accept